STAT+: GSK sees its return to cancer start to pay off

GSK's oncology push is starting to pay off. In the past week, a GSK cancer drug was approved for another tumor type, the company presented the first data from a global study of its next-generation chemotherapy, and a drug GSK licensed featured in a presidential session at ESMO. GSK expects approval of another new lung cancer drug in the coming weeks.